DOCSLIB.ORG

Drug Repurposing Compound Library Plus (96-Well)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Repurposing Compound Library Plus (96-Well) • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Drug Repurposing Compound Library Plus (96-well) Product Details: Catalog Number: CS-L035P Formulation: A collection of 3924 bioactive compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L035P-Part A-1 1 2 3 4 5 6 7 8 9 10 11 12 Flavopiridol a Empty Vonoprazan Peretinoin Tomivosertib Faropenem Flavopiridol (Hydrochlorid Semagacesta Mitoquinone Taranabant Delpazolid Empty daloxate e) t (mesylate) Varenicline AQ-13 b Empty DSM265 GSK- Varenicline (Hydrochlorid Varenicline Trifarotene 9-amino-CPT dihydrochlorid Remetinostat Isavuconazon Empty 2881078 e) (Tartrate) e ium (sulfate) K-604 c Empty Diroximel Nevanimibe dihydrochlorid Pactimibe Pactimibe Linaprazan BFH772 Odanacatib Cadazolid Treprostinil Empty fumarate hydrochloride e (sulfate) Rilmenidine d Empty Paquinimod AEE788 Plerixafor Esaxerenone Visomitin (hemifumarat Rilmenidine Fisogatinib FT011 GSK2256098 Empty e) (phosphate) e Empty Avadomide Aprepitant (S)-Crizotinib MSDC 0160 Abscisic acid Tempol Flopropione Acriflavine Davercin Spiramycin Empty Sodium Landiolol AZD5153 (6- f Empty stibogluconat Saponins (hydrochlorid BMS-986020 BMS-986020 Ticagrelor Axitinib Hydroxy-2- Fosfluconazol Pipamperone Empty e e) (sodium) naphthoic e Pirmenol g Empty Eganelisib HT-2157 Lanabecestat CXD101 Ritlecitinib Setogepram Rimacalib (hydrochlorid D-Serine Futibatinib Empty (sodium salt) e) TAK-659 h Empty 3-AP BGP-15 (hydrochlorid Navitoclax ABX464 Bisantrene Zibotentan Acelarin Simurosertib Olcegepant Empty e) Plate layout: CS-L035P-Part A-2 1 2 3 4 5 6 7 8 9 10 11 12 (2- Empty Choline Sarcosine Q203 Brensocatib Acetylcholine MK-8998 Hydroxypropy TG100-115 Tesmilifene Filibuvir Empty a (bitartrate) (iodide) l)-β- (fumarate) Milademetan b Empty T807 JNJ- Vorapaxar Asenapine Silodosin Barasertib- (tosylate Barasertib Vadadustat Veliparib Empty 39758979 HQPA hydrate) Veliparib Trilaciclib c Empty Iberdomide FK614 (dihydrochlori Allopurinol Gestrinone Ralfinamide (hydrochlorid Zanubrutinib Ibuprofen LY3214996 Empty de) riboside e) piconol d Empty AZD-5991 Linrodostat Avapritinib GDC-0077 GSK3326595 BMS-986158 Roblitinib Bosutinib Gefapixant Nilotinib Empty Nilotinib Tedatioxetine e Empty (monohydroc Tozasertib Olaparib Ilaprazole Aticaprant (hydrobromid GSK2982772 Ziritaxestat EDO-S101 Danusertib Empty hloride e) Dasatinib Blarcamesine f Empty Dasatinib (hydrochlorid BMS-986142 TG 100801 Miridesap (hydrochlorid Linsitinib TNP-470 Sepantronium CM-4620 Empty e) e) (bromide) Ruboxistaurin g Empty Prostaglandin (hydrochlorid Selitrectinib CPI-444 Navarixin AZD4635 BMS-754807 Rucaparib Rilapladib Sorafenib Empty E2 e) (Camsylate) Tandutinib h Empty Sorafenib Tandutinib (hydrochlorid Linperlisib Cediranib Apimostinel Amuvatinib Dovitinib Pazopanib Masitinib Empty (Tosylate) e) (lactate) Plate layout: CS-L035P-Part A-3 1 2 3 4 5 6 7 8 9 10 11 12 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Retaspimycin a Empty Masitinib (Hydrochlorid Tanespimycin BIIB021 Luminespib Everolimus Rapamycin Vorinostat Ixabepilone Panobinostat Empty (mesylate) e) Gaboxadol b Empty Belinostat Bortezomib Motesanib Motesanib Midostaurin THIP (hydrochlorid Saracatinib Telaprevir Boceprevir Empty (Diphosphate) e) Afatinib c Empty Danoprevir Mericitabine Simeprevir RAF265 PD0325901 Sunitinib Vandetanib Afatinib (dimaleate) Edoxaban Empty Edoxaban Dabigatran d Empty Edoxaban (tosylate Betrixaban Dabigatran etexilate Linagliptin Saxagliptin Tarenflurbil Narlaprevir Gusacitinib Empty (tosylate) monohydrate) etexilate (mesylate) BET e Empty LY3200882 Repotrectinib bromodomain Zuranolone AAI101 Proxalutamid Doramapimod Amibegron Desidustat Neflamapimo Empty inhibitor e hydrochloride d Regorafenib f Empty Toceranib Toceranib Regorafenib Bepridil (monohydrate BMS-690514 Proglumide Brivanib Brivanib Talniflumate Empty (phosphate) hydrochloride ) (sodium) (alaninate) Tirbanibulin Fasudil Raltegravir g Empty Foretinib Stiripentol Tirbanibulin (dihydrochlori Tirbanibulin (Hydrochlorid Enzastaurin Sotrastaurin Raltegravir (potassium Empty de) (Mesylate) e) salt) MK-2206 Canertinib Samuraciclib h Empty (dihydrochlori GW-870086 MAK683 Canertinib AZD7624 (dihydrochlori (hydrochlorid Seclidemstat Ensartinib Trimetrexate Empty de) de) e) hydrochloride Plate layout: CS-L035P-Part A-4 1 2 3 4 5 6 7 8 9 10 11 12 a Empty Semaxinib Sutezolid Linezolid Emricasan CTS-1027 VX-702 Asciminib Islatravir Losmapimod PH-797804 Empty Fedratinib b Empty IDH-305 Cintirorgon Vorasidenib Pamiparib Lanifibranor Talmapimod Fedratinib (hydrochlorid Milciclib Vismodegib Empty e hydrate) Dapagliflozin Empty Balapiravir Pralatrexate Capsaicin Dapagliflozin ((2S)-1,2- Canagliflozin Ixazomib Ixazomib Delanzomib TAK-715 Empty c propanediol, citrate Daclatasvir Melflufen d Empty (dihydrochlori Daclatasvir Eprotirome Fasiglifam Pevonedistat Dinaciclib Cobicistat Lexibulin (hydrochlorid Tipifarnib Empty de) hydrochloride e) Pomaglumeta Pimonidazole e Empty d methionil Orteronel Rifalazil (hydrochlorid Orantinib Fidarestat Meclinertant Darapladib Telatinib Tasquinimod Empty (hydrochlorid e) Tariquidar Empty PF 04531083 Sulopenem Piromelatine Betulinic acid Varlitinib Eniluracil Evofosfamide Tegobuvir Tariquidar (methanesulf Empty f onate, Sarpogrelate g Empty Nelotanserin Temanogrel Ketanserin Ketanserin Nomegestrol (hydrochlorid SRX246 Ponesimod Nevirapine Delavirdine Empty (tartrate) acetate e) (mesylate) Gatifloxacin h Empty Efavirenz Rilpivirine GSK 3 Gatifloxacin (hydrochlorid Flurbiprofen Valproic acid BNC210 Valproic acid 5-Azacytidine Empty Inhibitor IX e) (sodium salt) Plate layout: CS-L035P-Part A-5 1 2 3 4 5 6 7 8 9 10 11 12 Trabodenoso Alagebrium Rucaparib a Empty Lobaplatin Zamicastat MMV390048 n Liarozole chloride Bimosiamose (phosphate) Rucaparib Niraparib Empty Niraparib b Empty Lidorestat (hydrochlorid Niraparib PF-00446687 Vapendavir Larazotide SB-705498 Carcainium BIO-11006 Salfaprodil Empty e) (tosylate) (diphosphate) (acetate) (chloride) (acetate) (free base) Chloroquinox c Empty Salfaprodil Tefinostat Arimoclomol Neticonazole Tiaprofenic Mitoguazone Voclosporin aline Hydrocortison Centhaquin Empty (maleate) acid sulfonamide e buteprate Nebentan Ningetinib d Empty Pridopidine Saredutant S 3304 Nebentan (potassium) MAP4343 Tosylate Ningetinib PZ-128 PF-03463275 Empty Delapril Asimadoline e Empty Bacitracin Selamectin Almitrine Azosemide β-Elemene (hydrochlorid Deserpidine AZD4205 Tetrahydrobio (hydrochlorid Empty mesylate e) pterin e) Clodronate f Empty Epristeride Tropifexor PAT-1251 Abrocitinib AZD-8529 AZD-8529 Arundic Acid Ectoine (disodium Benorilate Empty (mesylate) tetrahydrate) Potassium 5- Desoxycortico g Empty guaiacolsulfo Inosine Acetylsalicylic A40926 Cilomilast Ritanserin Hyaluronidas sterone Isosulfan blue Rezafungin Empty nate pranobex acid e pivalate (acetate) Ganaplacide Almorexant h Empty Armillarisin A Ferric maltol MSDC-0602 (hydrochlorid GET73 Almorexant (hydrochlorid Bitopertin Pemetrexed Pemetrexed Empty e) e) (disodium) Plate layout: CS-L035P-Part A-6 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com 1 2 3 4 5 6 7 8 9 10 11 12 Inosine 5'- Lanicemine Melitracen a Empty Raltitrexed monophosph (dihydrochlori AZD5423 (hydrochlorid Promestriene Sultiame (Z)- Brequinar PF-04937319 Empty ate (disodium de) e) Thiothixene Nolatrexed b Empty Gamithromyci GW 501516 Cefodizime Cefodizime Emedastine Talazoparib Pretomanid Delamanid dihydrochlorid Arterolane Empty n (sodium) tosylate e Foliglurax c Empty Vipadenant (monohydroc Aripiprazole Clotrimazole Istradefylline Preladenant Icatibant Apararenone Padsevonil Poseltinib Empty hloride) Lauroxil (acetate) Seltorexant d Empty Rosiptor Seltorexant (hydrochlorid Sofpironium Tucidinostat Vamorolone Vorolanib Acrizanib Balovaptan Baloxavir Empty e) (bromide) marboxil Inarigivir e Empty Baloxavir Dorzagliatin soproxil Mavacamten Praliciguat Razuprotafib Tapinarof Adavivint Alobresib Elenbecestat Empty Parsaclisib f Empty Enarodustat Firibastat Fulacimstat Lazertinib Olinciguat (hydrochlorid Vecabrutinib Belvarafenib Cilofexor Difamilast Empty e) Lanraplenib Tepilamide Valemetostat g Empty Edicotinib Lanraplenib (succinate) Licogliflozin Nemorexant Nidufexor Pemigatinib Tegatrabetan fumarate (tosylate) Empty Acoramidis h Empty Odevixibat Reldesemtiv Soticlestat Danicamtiv Selgantolimo Danegaptide Ziresovir (hydrochlorid Giredestrant Posenacaftor Empty d Hydrochloride e) (sodium) Plate layout: CS-L035P-Part A-7 1 2 3 4 5 6 7 8 9 10 11 12 Cerivastatin a Empty Rezivertinib Tolebrutinib Zandelisib Camicinal Aniracetam CX516 Mibampator S 18986 Farampator (sodium) Empty Gemcabene Arachidonic Momelotinib b Empty ASTX660 Gemcabene (calcium) IRAK4-IN-7 acid BMS-813160 Momelotinib sulfate Vadimezan Ensulizole Empty Obatoclax Lenvatinib Pomalidomid c Empty (Mesylate) Alisertib MK-0752 Tivozanib Crisaborole Tavaborole Lenvatinib (mesylate) Amonafide e Empty Trametinib d Empty ENMD-2076 ENMD-2076 Adavosertib Tozadenant Ibrutinib Ibrutinib Trametinib (DMSO ZSET1446 Rivastigmine Empty (Tartrate) (Racemate) solvate) (tartrate)
Load more

Recommended publications
  • Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal
    testinal & in D o i tr g s e Journal of Gastrointestinal & a s t G i v f e o Narayanan et al., J Gastrointest Dig Syst 2018, 8:1 S l y a s n r ISSN: 2161-069Xt Digestive System DOI: 10.4172/2161-069X.1000553 e u m o J Research Article Open Access Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal- related Symptoms of Functional Dyspepsia Varsha Narayanan*, Amit Bhargava and Shailesh Pallewar 1Department of Medical Services and Research, Lupin Ltd., India *Corresponding author: Narayanan V, Department of Medical Services and Research, Lupin Ltd., Mumbai, India, Tel: +912266402222; E-mail: [email protected] Received date: February 09, 2018; Accepted date: February 21, 2018; Published date: February 27, 2018 Copyright: © 2018 Narayanan V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: Functional Dyspepsia (FD) is a highly prevalent clinical condition that imposes negative economic burden on health-care system as well as greatly impairs quality of life. Treatment of non-specific and bothersome meal-related FD symptoms like post-prandial fullness, upper abdominal bloating and early satiety, is a therapeutic challenge for the clinicians as poorly-defined and ill-understood pathogenesis has hampered efforts to develop effective treatments. Acotiamide is first-in-class drug that exerts its gastro-kinetic effect by enhancing acetylcholine release. Though evidence of its efficacy and tolerance are available through randomized clinical trials, real world data from its regular in-clinic use is lacking.
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • PN0496-Acotiamide.Pdf
    Acotiamide hydrochloride hydrate (Acofide®) 盐酸阿考替胺 Z-338 in Zeria; YM-443 in Astellas Tablet, oral, EQ 100 mg acotiamide Acotiamide is a peripheral acetylcholinesterase inhibitor, indicated for the treatment of functional dyspepsia (FD), which was first-in-class drug to treat FD in the world and approved in 2013 by Japan PMDA. It was originally discovered by Zeria, and co-developed with Astellas. The drug is co-marketing in Japan with a single brand name. The human recommended starting dose is 100 mg at a time, and 3 times a day before meals. Worldwide Key Approvals Global Sales ($Million) Key Substance Patent Expiration 2016-May (US5981557A) 2016-May (EP0870765B1) 2013-Mar (JP) Not available 2021-May (JP3181919B2) 2016-May (CN1063442C) Mechanism of Action Acotiamide hydrochloride hydrate is an acetylcholinesterase (AChE) inhibitor and enhanced the acetylcholine (ACh)-induced contraction and motility of the gastric antrum and the gastric body. Target Binding Selectivity In vitro Efficacy In vivo Efficacy Mixed pattern: Ki1= 0.61 µM Effect dose of contraction in gastric sample: Significantly improved the gastrointestinal motility: Ki2= 2.7 µM ACh-induced: at 1 µM In normal and gastric hypomotility dogs: at 10 mg/kg. Inhibition: IC50= 3 µM Electrical-induced: at 0.3 µM In gastric hypomotility rats: at 100 mg/kg. Pharmacokinetics Parameters Rats Dogs Healthy Humans 3 10 3 10 50 mg 100 mg 200 mg 400 mg 800 mg Dose (mg/kg) (i.v.) (p.o.) (i.v.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) Tmax (hr) - 0.08 - 0.5 2.75 2.42 2.08 2.25 2.13 Cmax
    [Show full text]
  • Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic
    Author Manuscript Published OnlineFirst on January 19, 2016; DOI: 10.1158/0008-5472.CAN-15-1619 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. Vanessa F. Merino1,7, Nguyen Nguyen1,7, Kideok Jin1, Helen Sadik1, Soonweng Cho1, Preethi Korangath1, Liangfeng Han1, Yolanda M. N. Foster1, Xian C. Zhou1, Zhe Zhang1, Roisin M. Connolly1, Vered Stearns1, Syed Z. Ali2, Christina Adams2, Qian Chen3, Duojia Pan3, David L. Huso4, Peter Ordentlich5, Angela Brodie6, Saraswati Sukumar1*. 1Department of Oncology, 2Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, 3Department of Molecular Biology and Genetics, 4Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 5Syndax Pharmaceuticals, Department of Translational Medicine, Waltham, MA, USA, 6Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA. 7These authors contributed equally. *Correspondence: Saraswati Sukumar, PhD, 1650 Orleans Street, Baltimore, MD, 21231, Ph. 410-614-2479, [email protected] and Vanessa F. Merino, PhD, 1650 Orleans Street, Baltimore, MD, 21231, Ph. 410-614-4075, [email protected]. Key words: Breast, cancer, entinostat, RAR-beta, epigenetic Grant Support: This work was funded by the DOD BCRP Center of Excellence Grant W81XWH-04-1-0595 to S.S, and DOD BCRP, W81XWH-09-1-0499 to V.M. Downloaded from cancerres.aacrjournals.org on September 27, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on January 19, 2016; DOI: 10.1158/0008-5472.CAN-15-1619 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • An Overview of the Role of Hdacs in Cancer Immunotherapy
    International Journal of Molecular Sciences Review Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy Debarati Banik, Sara Moufarrij and Alejandro Villagra * Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, 800 22nd St NW, Suite 8880, Washington, DC 20052, USA; [email protected] (D.B.); [email protected] (S.M.) * Correspondence: [email protected]; Tel.: +(202)-994-9547 Received: 22 March 2019; Accepted: 28 April 2019; Published: 7 May 2019 Abstract: Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi candidates in preclinical studies in cancer and other diseases as well as the FDA-approval towards clinical use for specific agents. In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis. We have also included a brief overview of the classification of HDACis as well as their various roles in physiological and pathophysiological scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer. Given the critical role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME. We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clinical trials or show promising preclinical effects for future consideration.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Analysis of Metals in Surface Water Samples
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex I Analysis of metals in surface water samples Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Surface water samples Cd (ug/L) Pb (ug/L) Hg (ug/L) Ni (ug/L) As (ug/L) Cr (ug/L) Cu (ug/L) Zn (ug/L) Metals – limit values 0.15** 1.2** 0.07*** 4** 24* 9.0* 1.6* 9.6* Table 1: Results of analyses of Sampling point 1 filtered <LOQ <LOQ <LOQ <LOQ 3.38 <LOQ 1.15 4.0 metals in surface water samples. Sampling point 2 filtered 0.547 <LOQ <LOQ 1.845 <LOQ 0.666 1.94 26.5 The values represent dissolved Sampling point 3 filtered <LOQ <LOQ <LOQ <LOQ 1.99 <LOQ 0.89 4.1 concentrations (after filtration of Sampling point 4 filtered <LOQ <LOQ <LOQ 1.33 <LOQ <LOQ 4.21 9.2 the samples). Numbers Sampling point 5 filtered 2.66 <LOQ <LOQ <LOQ <LOQ 2.35 9.39 20.6 highlighted in orange colour Sampling point 6 filtered <LOQ <LOQ <LOQ <LOQ 2.62 <LOQ 4.95 6.9 indicate exceedance of the Sampling point 7 filtered 0.345 <LOQ <LOQ <LOQ <LOQ 0.777 6.06 38.4 toxicity threshold values. Sampling point 8 filtered <LOQ <LOQ <LOQ <LOQ 2.65 <LOQ 1.03 61.7 Sampling point 9 filtered 0.129 <LOQ <LOQ <LOQ 2.29 0.85 5.36 16.4 Sampling point 10 filtered <LOQ <LOQ <LOQ 1.772 <LOQ <LOQ <LOQ 7.9 Sampling point 11 filtered 0.292 <LOQ <LOQ <LOQ <LOQ 1.31 0.82 11.9 Sampling point 12 filtered 0.328 <LOQ <LOQ <LOQ <LOQ 3.89 1.34 2.6 Sampling point 13 filtered <LOQ
    [Show full text]
  • Spectrofluorometric Determination of Some Β-Blockers in Tablets And
    ORIGINAL ARTICLES Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia Spectrofluorometric determination of some b-blockers in tablets and human plasma using 9,10-dimethoxyanthracene-2-sodium sulfonate H. Abdine, M. A. Sultan, M. M. Hefnawy, F. Belal Received April 16, 2004, accepted June 2, 2004 Prof. Dr. F. Belal, Department of Pharmaceutical Chemistry, College of Pharmacy, P.O.Box 2457, King Saud University, Riyadh 11451, Saudi Arabia [email protected] Pharmazie 60: 265–268 (2005) A simple and sensitive spectrofluorometric method was developed for the quantitative determination of some b-blockers, namely arotinolol, atenolol and labetalol as hydrochloride salts. The method is based on the reaction of these drugs as n-electron donors with the fluorogenic reagent 9,10-dimethoxy-2- anthracene sulfonate (DMAS) as p-acceptor in acidic medium. The obtained ion-pairs were extracted into chloroform and measured spectrofluorometrically at 452 nm after excitation at 385 nm. The fluor- escence intensity-concentration plots are rectilinear over the ranges of 0.5–5 mg Á ml1, 1.0–11.0 mg Á ml1 and 0.6–6.4 mg Á ml1 for labetalol, atenolol and arotinolol, respectively. The different parameters affect- ing the reaction pathway were thoroughly studied and optimized. No interference was observed from the common pharmaceutical excipients. The proposed method was successfully applied to the analy- sis of tablets and the results were statistically compared with those obtained by reference methods. The method was further extended to the in vitro determination of the drugs in spiked human plasma, the% recoveries (n ¼ 3) ranged from 96.98 Æ 1.55 to 98.28 Æ 2.19.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Vorinostat—An Overview Aditya Kumar Bubna
    E-IJD RESIDENTS' PAGE Vorinostat—An Overview Aditya Kumar Bubna Abstract From the Consultant Vorinostat is a new drug used in the management of cutaneous T cell lymphoma when the Dermatologist, Kedar Hospital, disease persists, gets worse or comes back during or after treatment with other medicines. It is Chennai, Tamil Nadu, India an efficacious and well tolerated drug and has been considered a novel drug in the treatment of this condition. Currently apart from cutaneous T cell lymphoma the role of Vorinostat for Address for correspondence: other types of cancers is being investigated both as mono-therapy and combination therapy. Dr. Aditya Kumar Bubna, Kedar Hospital, Mugalivakkam Key Words: Cutaneous T cell lymphoma, histone deacytelase inhibitor, Vorinostat Main Road, Porur, Chennai - 600 125, Tamil Nadu, India. E-mail: [email protected] What was known? • Vorinostat is a histone deacetylase inhibitor. • It is an FDA approved drug for the treatment of cutaneous T cell lymphoma. Introduction of Vorinostat is approximately 9. Vorinostat is slightly Vorinostat is a histone deacetylase (HDAC) inhibitor, soluble in water, alcohol, isopropanol and acetone and is structurally belonging to the hydroxymate group. Other completely soluble in dimethyl sulfoxide. drugs in this group include Givinostat, Abexinostat, Mechanism of action Panobinostat, Belinostat and Trichostatin A. These Vorinostat is a broad inhibitor of HDAC activity and inhibits are an emergency class of drugs with potential anti- class I and class II HDAC enzymes.[2,3] However, Vorinostat neoplastic activity. These drugs were developed with the does not inhibit HDACs belonging to class III. Based on realization that apart from genetic mutation, alteration crystallographic studies, it has been seen that Vorinostat of HDAC enzymes affected the phenotypic and genotypic binds to the zinc atom of the catalytic site of the HDAC expression in cells, which in turn lead to disturbed enzyme with the phenyl ring of Vorinostat projecting out of homeostasis and neoplastic growth.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]